Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension
Key Points:
- Selexipag, a selective prostacyclin receptor agonist, plays a crucial role in triple combination therapy for PAH management.
- Differences in treatment sequences (e.g., ERA + PDE-5i + selexipag vs. PDE-5i + ERA + selexipag) may impact hemodynamic improvements and long-term prognosis.
- Optimizing therapy sequencing can enhance patient outcomes, reduce hospitalizations, and improve quality of life in PAH management.
Description
This study evaluates the effects of various sequential triple oral combination therapies incorporating selexipag on clinical outcomes in patients with pulmonary arterial hypertension (PAH). It explores how different treatment sequences influence disease progression, functional capacity, and survival.
Be the first to review “Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension”
Reviews
There are no reviews yet.